Blood type may be linked to the severity of COVID-19, according to a study. The research suggests people with type A blood have a higher risk of being infected with the coronavirus and developing worse symptoms. The study also suggested other genetic factors may play a role. (Reuters)

The Trump administration has proposed changes that encourage a value-based pricing system. The administration proposed changes to how drugmakers can report their prices to Medicaid, making it easier to enter contracts that tie payment to patient outcomes. (BioPharma Dive)

The majority of Americans are concerned pharma will use COVID-19 to raise drug prices. A poll found nearly 9 in 10 Americans had some concern about price hikes. Just over half were very concerned and 33% were somewhat concerned. (STAT)

A court has ruled in favor of Mylan in a patent dispute with Biogen. Biogen attempted to stop Mylan from launching a generic version of its multiple sclerosis drug Tecfidera, but the court ruled that the asserted claims of Biogen’s patent were invalid. (Reuters)

Coronavirus antibodies may not last long, according to study. A study published in Nature suggested that antibodies from COVID-19 may only last two or three months. However, scientists said even low levels of antibodies can protect people from reinfection. (The New York Times)